Literature DB >> 1859185

Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease.

C W Olanow1, L L Gauger, J M Cedarbaum.   

Abstract

We studied the pharmacokinetics of levodopa and its metabolites in plasma and ventricular cerebrospinal fluid in 4 parkinsonian patients with indwelling Ommaya reservoirs placed at the time of previous adrenal-medullary to caudate nucleus transplantation. Cerebrospinal fluid levodopa levels were 11.9% of those in plasma. Motor performance and dyskinesia correlated more closely with the time course of the appearance of levodopa in the ventricular cerebrospinal fluid than with the plasma levodopa concentration and did not correlate with plasma 3-O-methyldopa or cerebrospinal fluid 3-O-methyldopa or homovanillic acid. Our data confirm that the wearing off of the levodopa effect in patients with advanced Parkinson's disease is a function of drug concentration in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1859185     DOI: 10.1002/ana.410290516

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  19 in total

1.  Parkinson disease: the controversy of levodopa toxicity in Parkinson disease.

Authors:  Theresa A Zesiewicz
Journal:  Nat Rev Neurol       Date:  2011-12-26       Impact factor: 42.937

2.  Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.

Authors:  H Baas; F Zehrden; R Selzer; R Kohnen; J Loetsch; S Harder
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment.

Authors:  Pauline Belujon; Daniel J Lodge; Anthony A Grace
Journal:  Mov Disord       Date:  2010-08-15       Impact factor: 10.338

Review 4.  Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?

Authors:  M G Murer; R Raisman-Vozari; O Gershanik
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

5.  Evaluation of levodopa and carbidopa antioxidant activity in normal human lymphocytes in vitro: implication for oxidative stress in Parkinson's disease.

Authors:  Monica Colamartino; Massimo Santoro; Guglielmo Duranti; Stefania Sabatini; Roberta Ceci; Antonella Testa; Luca Padua; Renata Cozzi
Journal:  Neurotox Res       Date:  2014-10-30       Impact factor: 3.911

Review 6.  Optimising levodopa therapy for the management of Parkinson's disease.

Authors:  Fabrizio Stocchi
Journal:  J Neurol       Date:  2005-10       Impact factor: 4.849

Review 7.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation.

Authors:  S Harder; H Baas; N Bergemann; L Demisch; S Rietbrock
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

Review 9.  Concentration-effect relationship of levodopa in patients with Parkinson's disease.

Authors:  S Harder; H Baas; S Rietbrock
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

10.  Depression of Serotonin Synaptic Transmission by the Dopamine Precursor L-DOPA.

Authors:  Stephanie C Gantz; Erica S Levitt; Nerea Llamosas; Kim A Neve; John T Williams
Journal:  Cell Rep       Date:  2015-07-30       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.